TNF-α blocker effect of naringenin-loaded sericin microparticles that are potentially useful in the treatment of psoriasis

Int J Mol Sci. 2014 Aug 6;15(8):13624-36. doi: 10.3390/ijms150813624.

Abstract

This study aims to evaluate the effect of combined use of the racemic flavanone Naringenin (NRG) and the protein sericin as TNF-α blockers. Sericin (SMs) and (R/S) NRG-loaded Sericin (SNRGMs) microparticles were prepared by spray-drying, characterized in terms of morphology and particle size distribution, and encapsulation efficiency was determined. Concerning morphology and particle size distribution of microparticles, results indicated that they were not affected by the presence of NRG. The encapsulation efficiency was almost quantitative (93%), thus proving that sericin can be advantageously loaded with (R/S) NRG. Biological evaluation of (R/S) NRG, SMs and SNRGMs was then performed in lipopolysaccharide (LPS)-stimulated human peripheral blood mononuclear cells (hPBMC). SNRGMs resulted cytotoxic at the higher dose used (200 μg/mL) and the effect was greater than (R/S) NRG alone. Moreover, even if sericin alone was not effective in suppressing LPS-induced serum TNF-α levels, SNRGMs loaded with 9.3% of (R/S) NRG were significantly more potent than (R/S) NRG alone. In summary, this study provides the proof of concept that sericin-based microspheres loaded with TNF-α-blockers could contribute to the down regulation of the cytokine and represents the starting point for the development of new topical formulations for the treatment of middle-stage psoriasis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cells, Cultured
  • Chemistry, Pharmaceutical
  • Cytokines / metabolism
  • Down-Regulation / drug effects
  • Flavanones / chemistry
  • Flavanones / pharmacology
  • Flavanones / therapeutic use*
  • Humans
  • Leukocytes, Mononuclear / cytology
  • Leukocytes, Mononuclear / drug effects
  • Leukocytes, Mononuclear / metabolism
  • Lipopolysaccharides / toxicity
  • Microspheres*
  • Particle Size
  • Psoriasis / drug therapy*
  • Sericins / chemistry*
  • Sericins / pharmacology
  • Sericins / therapeutic use
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Cytokines
  • Flavanones
  • Lipopolysaccharides
  • Sericins
  • Tumor Necrosis Factor-alpha
  • naringenin